240 related articles for article (PubMed ID: 19641317)
1. Role of the endocannabinoid system in abdominal obesity and the implications for cardiovascular risk.
Rosenson RS
Cardiology; 2009; 114(3):212-25. PubMed ID: 19641317
[TBL] [Abstract][Full Text] [Related]
2. The endocannabinoid system as a novel approach for managing obesity.
Lillo JL
J Am Osteopath Assoc; 2007 Apr; 107(4 Suppl 2):S12-20. PubMed ID: 17784530
[TBL] [Abstract][Full Text] [Related]
3. Endocannabinoid system and cardiometabolic risk.
Saavedra LE
Clin Pharmacol Ther; 2007 Nov; 82(5):591-4. PubMed ID: 17898706
[TBL] [Abstract][Full Text] [Related]
4. Effect of blockage of the endocannabinoid system by CB(1) antagonism on cardiovascular risk.
Mach F; Montecucco F; Steffens S
Pharmacol Rep; 2009; 61(1):13-21. PubMed ID: 19307689
[TBL] [Abstract][Full Text] [Related]
5. The endocannabinoid system and cardiometabolic risk: effects of CB1 receptor blockade on lipid metabolism.
Deedwania P
Int J Cardiol; 2009 Jan; 131(3):305-12. PubMed ID: 18715660
[TBL] [Abstract][Full Text] [Related]
6. The endocannabinoid system: a new target for the regulation of energy balance and metabolism.
Després JP
Crit Pathw Cardiol; 2007 Jun; 6(2):46-50. PubMed ID: 17667864
[TBL] [Abstract][Full Text] [Related]
7. The endocannabinoid system: a promising target for the management of type 2 diabetes.
Scheen AJ
Curr Protein Pept Sci; 2009 Feb; 10(1):56-74. PubMed ID: 19275673
[TBL] [Abstract][Full Text] [Related]
8. [Impact of endocannabinoid system in modulation of cardiometabolic risk factors].
Sulcová A
Vnitr Lek; 2006 Jun; 52(6):615-8. PubMed ID: 16871766
[TBL] [Abstract][Full Text] [Related]
9. Contribution of CB1 blockade to the management of high-risk abdominal obesity.
Després JP; Lemieux I; Alméras N
Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S44-52. PubMed ID: 16570106
[TBL] [Abstract][Full Text] [Related]
10. [The endocannabinoid system].
Sudano I; Périat D; Noll G
Praxis (Bern 1994); 2008 Apr; 97(7):375-80. PubMed ID: 18548817
[TBL] [Abstract][Full Text] [Related]
11. Role of the endocannabinoid system in management of patients with type 2 diabetes mellitus and cardiovascular risk factors.
Davis SN; Perkins JM
Endocr Pract; 2007; 13(7):790-804. PubMed ID: 18194939
[TBL] [Abstract][Full Text] [Related]
12. Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders.
Silvestri C; Di Marzo V
Expert Opin Investig Drugs; 2012 Sep; 21(9):1309-22. PubMed ID: 22780328
[TBL] [Abstract][Full Text] [Related]
13. [Blocking the endocannabinoid system -- weight reduction and cardiovascular risk management].
Bramlage P; Böcking W; Kirch W
Dtsch Med Wochenschr; 2005 Mar; 130(12):665-8. PubMed ID: 15776349
[TBL] [Abstract][Full Text] [Related]
14. Blockade of the endocannabinoid system for the reduction of cardiometabolic risk factors.
Samaha FF; Chou CM
Obesity (Silver Spring); 2009 Feb; 17(2):220-5. PubMed ID: 19039319
[No Abstract] [Full Text] [Related]
15. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
Scheen AJ
J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513
[TBL] [Abstract][Full Text] [Related]
16. [The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant].
Boekholdt SM; Jukema JW; Peters RJ
Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2615-9. PubMed ID: 18161262
[TBL] [Abstract][Full Text] [Related]
17. Endocannabinoid system and cardio-metabolic risk.
Loh KY; Kew ST
Med J Malaysia; 2008 Oct; 63(4):348-50; quiz 351. PubMed ID: 19385504
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
19. The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome.
Kyrou I; Valsamakis G; Tsigos C
Ann N Y Acad Sci; 2006 Nov; 1083():270-305. PubMed ID: 17148745
[TBL] [Abstract][Full Text] [Related]
20. Pleiotropic effects of rimonabant: clinical implications.
Després JP
Curr Pharm Des; 2009; 15(5):553-70. PubMed ID: 19199981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
